NO. The problem is that there are so many treatments, which improve survival but are sub-optimal in effect for the patient.
Pharmaceutical drugs do NOT create new cells. IF there were still the patient cohort who were untreated, then MSB would have no problem sailing through the trials. IMO.
But don't let the secret out. Best to trigger emotional retail investors and clean up while you can. AGAIN.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-318
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.005(0.46%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $3.990M | 3.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 40609 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 44181 | 18 |
View Market Depth
| Last trade - 14.05pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |